This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

CHARM Preserved trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The CHARM-Preserved trial recruited 3023 patients with heart failure but no evidence of left ventricular dysfunction. Patients were randomised to treatment with candesartan or placebo.

There was no reduction in the primary outcome of the trial however there was a small reduction in admissions to hospital with heart failure.

Reference:

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777-81.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.